Cascade Chemistry, a pharmaceutical CDMO, began construction of new facilities to increase capacity to manufacture APIs under cGMP.
 
The new facilities, expected to be operational in 1Q22, will increase floor space almost three-fold and significantly add to its cGMP manufacturing capacity and scale. The $14 million expansion also includes 2,200 sq.-ft. of new analytical labs, a robust quality system and additional office space.


 
The 28,000-sq.-ft. building currently under construction will initially include five suites for Phase 1 and 2 cGMP manufacturing with flow hydrogenation and reactors up to 400 liters. Additional capacity for API Phase 3 and commercial scale cGMP manufacturing up to 1,000 liters will be added in 2022. The second 7,000-sq.-ft. building is reserved for future expansion.
 
“This expansion reflects our growing success as a reliable, experienced and flexible outsourcing partner with exceptional chemistry problem-solving expertise,” said Jeremiah Marsden, PhD, President of Cascade Chemistry. “Our customers are increasingly requesting our assistance in producing APIs for their clinical trials, and demand has outstripped our cGMP manufacturing capacity. We were fortunate to acquire two suitable buildings just 10 minutes from our current facility, and construction of new cGMP manufacturing suites that will greatly increase our clinical trial API production capacity is now underway.”